



TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

**UNAUDITED INTERIM FINANCIAL REPORT
FOR THE FINANCIAL QUARTER ENDED
31 MARCH 2025**

Contact

Level 11, No.11, Jalan Teknologi,
Taman Sains Selangor 1, PJU 5,
Kota Damansara
47810 Petaling Jaya, Selangor D.E.

Tel: +603 6287 1111
Fax: +603 6287 1212

www.tmclife.com

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2025

	Individual Quarter		9 months ended	
	Current Year Quarter	Preceding Year Quarter	Current Year To Date	Preceding Year Corresponding Period
	31/03/2025 RM'000	31/03/2024 RM'000	31/03/2025 RM'000	31/03/2024 RM'000
Revenue	89,872	86,073	252,265	272,294
Other operating income	1,240	806	3,194	3,330
Inventories and consumables	(30,565)	(24,296)	(83,028)	(76,901)
Staff costs	(30,501)	(27,408)	(88,716)	(79,757)
Other operating expenses	(19,446)	(14,584)	(51,149)	(42,678)
Depreciation and amortisation	(9,058)	(6,926)	(24,906)	(20,356)
Interest income	801	1,399	3,461	4,069
Finance costs	(2,291)	(2,607)	(7,103)	(7,721)
Profit before taxation	52	12,457	4,018	52,280
Taxation	(858)	(2,497)	(2,835)	(12,656)
(Loss) / Profit for the financial period, representing total comprehensive (loss) / income (net of tax) for the financial period	(806)	9,960	1,183	39,624
(Loss) / Profit for the financial period, representing total comprehensive (loss) / income (net of tax) for the financial period attributable to:-				
Owners of the parent	(806)	9,960	1,183	39,624
(Loss) / Profit per ordinary share attributable to the owners of the parent (sen)				
Basic	(0.05)	0.57	0.07	2.27
Diluted	(0.05)	0.57	0.07	2.27

The unaudited condensed consolidated statement of comprehensive income should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2025

	Attributable to owners of the parent			Total equity RM'000
	Share capital RM'000	Non-distributable	Distributable	
		Share options reserve RM'000	Retained profits RM'000	
Balance at 1 July 2024	625,986	1,316	260,732	888,034
Profit for the financial period, representing total comprehensive income (net of tax) for the financial period	-	-	1,183	1,183
Transactions with owners				
Share options granted under ESOS	-	15	-	15
Dividend paid	-	-	(38,616)	(38,616)
Total transactions with owners	-	15	(38,616)	(38,601)
Balance at 31 March 2025	625,986	1,331	223,299	850,616
Balance at 1 July 2023	625,986	1,415	234,558	861,959
Profit for the financial year, representing total comprehensive income (net of tax) for the financial year	-	-	40,648	40,648
Transactions with owners				
Share options granted under ESOS	-	55	-	55
Transfer within reserve for ESOS forfeited	-	(154)	154	-
Dividend paid	-	-	(14,628)	(14,628)
Total transactions with owners	-	(99)	(14,474)	(14,573)
Balance at 30 June 2024	625,986	1,316	260,732	888,034

The unaudited condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 June 2024 and the accompanying explanatory notes attached to the interim financial statements.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2025

	As At 31/03/2025 Unaudited RM'000	As At 30/06/2024 Audited RM'000
Non-current assets		
Property, plant and equipment	726,314	718,274
Intangible assets	202,779	206,494
Investment property	2,055	2,099
Deferred tax assets	193	315
Total non-current assets	931,341	927,182
Current assets		
Inventories	16,086	11,622
Trade and other receivables	64,621	51,592
Tax recoverable	11,325	10,755
Cash and bank balances	116,759	188,572
Total current assets	208,791	262,541
TOTAL ASSETS	1,140,132	1,189,723
Current liabilities		
Contract liabilities	514	525
Trade and other payables	74,073	72,035
Borrowings	34,518	23,488
Lease liabilities	1,578	1,814
Provision	89	381
Income tax payable	891	377
Total current liabilities	111,663	98,620
NET CURRENT ASSETS	97,128	163,921
Non-current liabilities		
Contract liabilities	298	257
Borrowings	152,641	179,270
Lease liabilities	543	662
Provision	530	222
Deferred tax liabilities	23,841	22,658
Total non-current liabilities	177,853	203,069
TOTAL LIABILITIES	289,516	301,689
NET ASSETS	850,616	888,034
Represented by:		
Equity attributable to owners of the parent		
Share capital	625,986	625,986
Reserves	1,331	1,316
Retained profits	223,299	260,732
TOTAL EQUITY	850,616	888,034
Net assets per share (RM)	0.49	0.51

The unaudited condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 June 2024 and the accompanying explanatory notes attached to the interim financial statements.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2025

	Current Year To Date 31/03/2025 RM'000	Preceding Year Corresponding Period 31/03/2024 RM'000
Cash flows from operating activities		
Profit before tax	4,018	52,280
Adjustments for :-		
Non-cash items	25,683	21,131
Interest expense	7,103	7,721
Interest income	(3,461)	(4,069)
Operating profit before changes in working capital	33,343	77,063
Changes in working capital		
Net change in current assets	(18,245)	2,813
Net change in trade and other payables and contract liabilities	5,273	(6,133)
Cash generated from operations	20,371	73,743
Interest paid	(6,951)	(7,667)
Net income tax paid	(1,586)	(355)
Net cash flows generated from operating activities	11,834	65,721
Cash flows generated from / (used in) investing activities		
Acquisition of property, plant and equipment	(30,487)	(18,282)
Acquisition of intangible assets	(449)	(427)
Proceeds from disposal of property, plant and equipment	3	-
Withdrawal/(Placement) of deposits placed with:-		
- financial institutions with original maturity of more than three (3) months	32,562	(30,821)
- deposits pledged	210	-
Interest received	3,461	4,069
Net cash flows generated from / (used in) investing activities	5,300	(45,461)
Cash flows used in financing activities		
Dividend paid	(38,616)	(14,628)
Payment of lease liabilities	(1,822)	(1,504)
Drawdown of term loans	-	2,972
Repayment of term loans	(15,075)	(11,322)
Repayment of hire purchase	(662)	(662)
Net cash flows used in financing activities	(56,175)	(25,144)
Net decrease in cash & cash equivalents	(39,041)	(4,884)
Cash & cash equivalents at beginning of the financial period	107,511	116,577
Cash & cash equivalents at end of the financial period	68,470	111,693
Cash & cash equivalents at end of the financial period		
Cash at banks and on hand	49,642	60,699
Deposits with licenced banks	67,117	131,782
	116,759	192,481
Less: Deposits with licensed banks (for more than 3 months)	(44,299)	(76,624)
Deposit pledged to a licenced bank	(1,530)	(1,704)
Cash restricted in use	(2,460)	(2,460)
	68,470	111,693

The unaudited condensed consolidated statement of cash flows should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.

**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2025**

**A EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING
STANDARDS ("MFRS")**

A1 BASIS OF PREPARATION

The interim financial report is not audited and has been prepared in compliance with Malaysian Financial Reporting Standards ("MFRS") 134 - Interim Financial Reporting and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of TMC Life Sciences Berhad and its subsidiaries ("the Group") for the financial year ended 30 June 2024. The explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant for understanding the changes in the financial position of the Group since the financial year ended 30 June 2024, and changes in financial performance since the preceeding year corresponding period.

The accounting policies and methods of computations used in the preparation of the financial statements are consistent with those adopted in the audited financial statements for the financial year ended 30 June 2024, except for the adoption of the new, revised and amendments to MFRS and IC Interpretations effective as of 1 January 2024 as issued by the Malaysian Accounting Standards Board, which does not have any significant impact on the financial statements of the Group.

A2 SEASONALITY OR CYCLICALITY OF OPERATIONS

The Group's business is typically impacted during festive and holiday periods when a decrease in patient load is anticipated.

A3 UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS

There were no material items or events that arose, which affected assets, liabilities, equity, net income or cash flows that are unusual by reasons of their nature, size or incidence.

A4 CHANGE IN ACCOUNTING ESTIMATES

During the financial period, the Group and the Company conducted a review to reassess the useful lives of their intangible assets. This reassessment was conducted in light of the future plan of the hospital information management system which has rendered the expected useful lives of certain intangible assets require revision.

As a result of this review, the useful lives of certain intangible assets were revised to better reflect the remaining expected useful lives of certain intangible assets, which were previously assessed to have useful lives of 4 years to 10 years, were revised to 2.9 years to 4.1 years.

This change is estimated to result in an increase in depreciation expense of RM2,967,000 for the full financial year.

The change in estimated useful lives is accounted for prospectively in accordance with MFRS 108 "Accounting Policies, Changes in Accounting Estimates and Errors".

A5 ISSUANCE AND REPAYMENT OF DEBT AND EQUITY SECURITIES

There were no issuance, cancellation, repurchases, resale and repayment of debt and equity securities in the current financial quarter under review.

A6 DIVIDEND PAID

During the financial period ended 31 March 2025, the Company paid a final single tier dividend of 0.4898 sen and a special single tier dividend of 1.7271 sen per ordinary share on 1,741,882,393 ordinary shares, amounting to RM38,615,761 in respect of the financial year ended 30 June 2024.

A7 SEGMENTAL INFORMATION

The Group operates mainly in Malaysia and is involved in the healthcare sector which includes providing specialist healthcare services in its multi disciplinary tertiary hospital and fertility centres.

A8 MATERIAL EVENT SUBSEQUENT TO THE END OF THE INTERIM REPORTING PERIOD

There was no material event subsequent to 31 March 2025 and up to the date of this report that would likely affect substantially the results of the operations of the Group.

A9 CHANGES IN THE COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the current quarter under review.

A10 CONTINGENT LIABILITIES OR CONTINGENT ASSETS

Financial guarantees

	31/03/2025	30/06/2024
	RM'000	RM'000
<u>Unsecured</u>		
Corporate guarantees given to licensed bank for banking facility granted to wholly-owned subsidiaries	187,159	202,758
Letter of guarantee given to suppliers	8,496	5,237
	<u>195,655</u>	<u>207,995</u>

A11 CAPITAL COMMITMENTS

The amount of commitments for capital expenditure as at 31 March 2025 is as follows:

	31/03/2025	30/06/2024
	RM'000	RM'000
Approved and contracted for	<u>29,452</u>	<u>49,325</u>

A12 SIGNIFICANT RELATED PARTY TRANSACTIONS

There were no significant related party transactions during the quarter under review.

**NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2025**

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD (“BURSA SECURITIES”)

B1 REVIEW OF THE PERFORMANCE OF THE GROUP

Analysis of performance

Review of results for the financial quarter (3 months ended 31 March 2025 versus 3 months ended 31 March 2024)

	3 months ended	
	31/03/2025	31/03/2024
	RM'000	RM'000
Revenue	89,872	86,073
Profit before taxation	52	12,457

For the quarter ended 31 March 2025, the Group recorded revenue of RM89.9 million, representing 4% increase compared to previous corresponding quarter. The growth in revenue was primarily driven by collaborations with Oncocare Medical Malaysia Sdn. Bhd. at the Oncology Centre in Thomson Hospital Kota Damansara ("THKD"). Profit before taxation stood at RM0.1 million in current quarter, marking a decline compared to the same quarter last year. The decrease in profit mainly attributable to the effects of discontinuation of customer contracts, higher operating expenses and increased depreciation.

Review of results for the financial period (9 months ended 31 March 2025 versus 9 months ended 31 March 2024)

	9 months ended	
	31/03/2025	31/03/2024
	RM'000	RM'000
Revenue	252,265	272,294
Profit before taxation	4,018	52,280

For the financial period ended 31 March 2025, the Group reported 7% decrease in revenue to RM252.3 million and 92% decrease in profit before taxation to RM4 million, compared to the corresponding period ended 31 March 2024. The significant decrease in profit before taxation was due to the effects of discontinuation of customer contracts, higher operating expenses and increased depreciation.

Material factors affecting the earnings and / or revenue of the Group

The material factors that affect the earnings and / or revenue of the Group are the successful recruitment of healthcare professionals in our facilities, additional bed capacity and additional services offered by the Group, higher case intensity handled, and continuous marketing effort to boost local and international branding.

**B2 MATERIAL CHANGE IN PROFIT / (LOSS) BEFORE TAX AS COMPARED WITH IMMEDIATE PRECEDING QUARTER
(3 months ended 31 March 2025 versus 3 months ended 31 December 2024)**

	3 months ended	
	31/03/2025	31/12/2024
	RM'000	RM'000
Revenue	89,872	80,426
Profit/(Loss) before taxation	52	(493)

Compared to the immediate preceding quarter ended 31 December 2024, revenue and profit before taxation increased by 12% and 111% respectively. The increase in both revenue and profit before taxation was driven by THKD's collaboration with Oncocare Medical Malaysia Sdn. Bhd., and lowering of discounts of customer contracts.

B3 PROSPECTS FOR THE FINANCIAL YEAR ENDING 30 JUNE 2025

The rising tariffs and trade restrictions between major economies have contributed to a slowdown in global economic growth. The effects of this economic deceleration are being felt across multiple industries, including healthcare sector. Key challenges arising from the tariff war include increased cost of medical supplies and supply chain disruption. The Group will continue to monitor and adjust its strategies proactively to mitigate risks and ensure long-term business sustainability.

Nevertheless, growth is expected to be driven by increased capacity at THKD and expected growth of Oncology Center in THKD. In addition, the Group is focusing on diversifying its customer base through international market expansion and new corporate clients. The Group is actively engaging with insurers to enhance the Group's performance and ensure a positive financial contribution.

B4 VARIANCE ON PROFIT FORECAST/PROFIT GUARANTEE

There is no profit forecast or profit guarantee for the financial period ended 31 March 2025.

B5 TAXATION

	Individual quarter		9 months ended	
	31/03/2025	31/03/2024	31/03/2025	31/03/2024
	RM'000	RM'000	RM'000	RM'000
In respect of current quarter / financial period				
Current tax expense	236	548	1,530	2,048
Deferred tax expense	622	1,949	1,305	10,608
	<u>858</u>	<u>2,497</u>	<u>2,835</u>	<u>12,656</u>

Tax provision during the current quarter refers to recognition of tax expense for profit making subsidiaries.

B6 STATUS OF CORPORATE PROPOSAL

There are no corporate proposals announced but not completed as at 14 May 2025, being the latest practicable date which shall not be earlier than 7 days from the date of this quarterly report.

B7 BORROWINGS

The Group's borrowings are as follows:-

	Long Term	Short Term	Total
	RM'000	RM'000	RM'000
As at 31 March 2025			
Secured - Denominated in Ringgit Malaysia	<u>152,641</u>	<u>34,518</u>	<u>187,159</u>
As at 30 June 2024			
Secured - Denominated in Ringgit Malaysia	<u>179,270</u>	<u>23,488</u>	<u>202,758</u>

Included in borrowings of the Group is an amount of Industrial Hire Purchase of RM664,000 (30 June 2024: RM1,328,000).

B8 MATERIAL LITIGATION

There was no material litigation as at the date of this report.

B9 DIVIDENDS

The Board does not recommend any dividend for the current quarter under review (previous year corresponding period ended 31 March 2024: NIL).

B10 EARNINGS PER SHARE (EPS)

	Individual quarter		9 months ended	
	31/03/2025	31/03/2024	31/03/2025	31/03/2024
(a) Basic EPS				
Net (loss) / profit attributable to owners of the parent (RM'000)	(806)	9,960	1,183	39,624
Weighted average number of ordinary shares in issue ('000)	1,741,882	1,741,882	1,741,882	1,741,882
EPS (sen)				
- Basic	(0.05)	0.57	0.07	2.27
(b) Diluted EPS				
Net (loss) / profit attributable to owners of the parent (RM'000)	(806)	9,960	1,183	39,624
Weighted average number of ordinary shares in issue ('000)	1,741,882	1,741,882	1,741,882	1,741,882
Effect of dilution ('000)	-	-	-	-
Adjusted weighted average number of shares ('000)	1,741,882	1,741,882	1,741,882	1,741,882
Diluted EPS (sen)				
- Diluted	(0.05)	0.57	0.07	2.27

Diluted EPS is calculated by dividing the profit attributable to owners of the parent by the weighted average of ordinary shares in issue during the financial year, adjusted to assume the conversion of dilutive potential ordinary shares.

For the current quarter ended 31 March 2025, share options granted under ESOS have not been included in the calculation of diluted earnings per share because they were anti-dilutive.

B11 AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The audit report of the preceding annual financial statements was unqualified.

B12 NOTE TO STATEMENT OF COMPREHENSIVE INCOME

	Individual quarter		9 months ended	
	31/03/2025	31/03/2024	31/03/2025	31/03/2024
	RM'000	RM'000	RM'000	RM'000
Interest income	801	1,399	3,461	4,069
Interest expense	(2,288)	(2,606)	(7,092)	(7,719)
Unwinding of discount on provision for restoration	(3)	(1)	(11)	(2)
Depreciation of property, plant and equipment, investment property and right-of-use assets	(7,355)	(6,403)	(20,742)	(18,800)
Amortisation of intangible assets	(1,703)	(523)	(4,164)	(1,556)
Impairment loss on receivables	(210)	(210)	(630)	(630)
Fair value charges on share options granted under ESOS	(5)	(13)	(15)	(40)
Property, plant and equipment written off	(1)	-	(13)	(39)
Gain on disposal of property, plant and equipment	2	-	2	-
Gain on derecognition of lease liability	1	41	1	41
Inventories written off	(14)	(21)	(122)	(107)

B13 DERIVATIVE FINANCIAL INSTRUMENTS

The Group did not enter into any derivative financial instruments which were outstanding as at 31 March 2025 and 30 June 2024.

B14 AUTHORISED FOR ISSUE

The condensed consolidated interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 21 May 2025.